How to improve R&D productivity: the pharmaceutical industry's grand challenge

被引:2271
作者
Paul, Steven M. [1 ]
Mytelka, Daniel S. [1 ]
Dunwiddie, Christopher T. [1 ]
Persinger, Charles C. [1 ]
Munos, Bernard H. [1 ]
Lindborg, Stacy R. [1 ]
Schacht, Aaron L. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
CHOLESTEROL; PCSK9; LDL; DISCOVERY; ATTRITION; MUTATIONS;
D O I
10.1038/nrd3078
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs. However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a number of years. Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity. We then propose specific strategies that could have the most substantial impact in improving R&D productivity.
引用
收藏
页码:203 / 214
页数:12
相关论文
共 45 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] Angell Marcia., 2005, The Truth about the Drug Companies: How They Deceive Us and What to Do about It
  • [3] [Anonymous], 2004, INNOVATION STAGNATIO
  • [4] [Anonymous], 2004, GOAL PROCESS ONGOING
  • [5] Bonabeau E, 2008, HARVARD BUS REV, V86, P96
  • [6] Prospects for productivity
    Booth, B
    Zemmel, R
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) : 451 - 457
  • [7] Modeling resource retirements for pharmaceutical red
    Bunch, PR
    Schacht, AL
    [J]. RESEARCH-TECHNOLOGY MANAGEMENT, 2002, 45 (01) : 48 - 56
  • [8] Cao Guoqing, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P238, DOI 10.2174/187153008786848286
  • [9] A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
    Chan, Joyce C. Y.
    Piper, Derek E.
    Cao, Qiong
    Liu, Dongming
    King, Chadwick
    Wang, Wei
    Tang, Jie
    Liu, Qiang
    Higbee, Jared
    Xia, Zhen
    Di, Yongmei
    Shetterly, Susan
    Arimura, Ziva
    Salomonis, Heather
    Romanow, William G.
    Thibault, Stephen T.
    Zhang, Richard
    Cao, Ping
    Yang, Xiao-Ping
    Yu, Timothy
    Lu, Mei
    Retter, Marc W.
    Kwon, Gayle
    Henne, Kirk
    Pan, Oscar
    Tsai, Mei-Mei
    Fuchslocher, Bryna
    Yang, Evelyn
    Zhou, Lei
    Lee, Ki Jeong
    Daris, Mark
    Sheng, Jackie
    Wang, Yan
    Shen, Wenyan D.
    Yeh, Wen-Chen
    Emery, Maurice
    Walker, Nigel P. C.
    Shan, Bei
    Schwarz, Margrit
    Jackson, Simon M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (24) : 9820 - 9825
  • [10] CHERTKOW J, 2008, TRENDS PHARM PORTFOL